Inactivated SARS-CoV-2 Variant Omicron, Lineage BQ.1.16 (USA/NY-Wadsworth-22050865-01/2022)

The Omicron subtype, BQ.1.16, a descendant of BA.5, has demonstrated increased transmissibility due to its ability to evade vaccine-induced and natural immunity. Emerging in late 2022, BQ.1.16 carries additional spike protein mutations that enhance the virus''s binding affinity for the ACE2 receptor, thereby facilitating faster entry and replication in host cells. Epidemiological studies have shown that it spreads more efficiently than earlier Omicron strains, leading to a surge in cases despite prior immunity. While BQ.1.16 retains the hallmark characteristics of lower severity within the Omicron lineage, its immune evasion capabilities present challenges for public health intervention. This variant''s pathogenesis involves an upper respiratory tract tropism, typically causing milder symptoms such as sore throat and fatigue, but can still present severe consequences in vulnerable populations such as the elderly and immunocompromised individuals.

The genomic structure of BQ.1.16 is determined by a series of mutations, particularly in the spike (S) protein, which shape its biological properties. Key mutations include R346T, K444T, and N460K, which collectively enhance immune evasion by altering antibody-binding epitopes. Structural analysis suggests that these changes stabilize the open conformation of the spike, promoting interaction with ACE2 while reducing neutralizing activity of monoclonal antibodies. Beyond the spike, BQ.1.16 inherits the genetic backbone of BA.5 but has acquired additional non-synonymous mutations in nonstructural proteins, such as NSP3 and NSP5, that may modulate viral replication. The variant''s genome comprises approximately 30,000 nucleotides, a characteristic of coronaviruses, with a mutation rate driven by RNA-dependent RNA polymerase errors and host editing mechanisms.